Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Microtubule destabilization and nuclear entry are sequential steps leading to toxicity in Huntington's disease.

Trushina E, Heldebrant MP, Perez-Terzic CM, Bortolon R, Kovtun IV, Badger JD 2nd, Terzic A, Estévez A, Windebank AJ, Dyer RB, Yao J, McMurray CT.

Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12171-6. Epub 2003 Oct 3.

2.

In vitro evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease.

Hackam AS, Singaraja R, Zhang T, Gan L, Hayden MR.

Hum Mol Genet. 1999 Jan;8(1):25-33.

PMID:
9887328
3.

A cellular model that recapitulates major pathogenic steps of Huntington's disease.

Lunkes A, Mandel JL.

Hum Mol Genet. 1998 Sep;7(9):1355-61.

PMID:
9700187
4.

Wild type Huntingtin reduces the cellular toxicity of mutant Huntingtin in mammalian cell models of Huntington's disease.

Ho LW, Brown R, Maxwell M, Wyttenbach A, Rubinsztein DC.

J Med Genet. 2001 Jul;38(7):450-2.

5.

Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions.

Lunkes A, Lindenberg KS, Ben-Haïem L, Weber C, Devys D, Landwehrmeyer GB, Mandel JL, Trottier Y.

Mol Cell. 2002 Aug;10(2):259-69.

6.

Huntingtin is cleaved by caspases in the cytoplasm and translocated to the nucleus via perinuclear sites in Huntington's disease patient lymphoblasts.

Sawa A, Nagata E, Sutcliffe S, Dulloor P, Cascio MB, Ozeki Y, Roy S, Ross CA, Snyder SH.

Neurobiol Dis. 2005 Nov;20(2):267-74.

PMID:
15890517
7.

Huntington's disease.

Davies S, Ramsden DB.

Mol Pathol. 2001 Dec;54(6):409-13. Review.

8.

Protein aggregation in Huntington's disease.

Hoffner G, Djian P.

Biochimie. 2002 Apr;84(4):273-8. Review.

PMID:
12106904
9.

Huntingtin contains a highly conserved nuclear export signal.

Xia J, Lee DH, Taylor J, Vandelft M, Truant R.

Hum Mol Genet. 2003 Jun 15;12(12):1393-403.

PMID:
12783847
10.

Requirement of an intact microtubule cytoskeleton for aggregation and inclusion body formation by a mutant huntingtin fragment.

Muchowski PJ, Ning K, D'Souza-Schorey C, Fields S.

Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):727-32. Epub 2002 Jan 15.

11.

Huntingtin fragments that aggregate go their separate ways.

DiFiglia M.

Mol Cell. 2002 Aug;10(2):224-5.

12.

Are there multiple pathways in the pathogenesis of Huntington's disease?

Aronin N, Kim M, Laforet G, DiFiglia M.

Philos Trans R Soc Lond B Biol Sci. 1999 Jun 29;354(1386):995-1003. Review.

13.

The selective vulnerability of nerve cells in Huntington's disease.

Sieradzan KA, Mann DM.

Neuropathol Appl Neurobiol. 2001 Feb;27(1):1-21. Review.

PMID:
11298997
14.

Huntington's disease: from huntingtin function and dysfunction to therapeutic strategies.

Borrell-Pagès M, Zala D, Humbert S, Saudou F.

Cell Mol Life Sci. 2006 Nov;63(22):2642-60. Review.

PMID:
17041811
15.

Nuclear localization of N-terminal mutant huntingtin is cell cycle dependent.

Martín-Aparicio E, Avila J, Lucas JJ.

Eur J Neurosci. 2002 Jul;16(2):355-9.

PMID:
12169117
16.
17.

Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease.

Wellington CL, Ellerby LM, Gutekunst CA, Rogers D, Warby S, Graham RK, Loubser O, van Raamsdonk J, Singaraja R, Yang YZ, Gafni J, Bredesen D, Hersch SM, Leavitt BR, Roy S, Nicholson DW, Hayden MR.

J Neurosci. 2002 Sep 15;22(18):7862-72.

Supplemental Content

Support Center